company background image
BCLI logo

Brainstorm Cell Therapeutics NasdaqCM:BCLI Stock Report

Last Price

US$0.56

Market Cap

US$29.4m

7D

17.6%

1Y

-77.4%

Updated

28 Mar, 2024

Data

Company Financials +

Brainstorm Cell Therapeutics Inc.

NasdaqCM:BCLI Stock Report

Market Cap: US$29.4m

BCLI Stock Overview

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases.

BCLI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Brainstorm Cell Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Brainstorm Cell Therapeutics
Historical stock prices
Current Share PriceUS$0.56
52 Week HighUS$3.46
52 Week LowUS$0.13
Beta0.21
1 Month Change55.56%
3 Month Change106.85%
1 Year Change-77.41%
3 Year Change-85.29%
5 Year Change-86.59%
Change since IPO67.32%

Recent News & Updates

Recent updates

Brainstorm Cell Therapeutics: Upcoming BLA In ALS

Aug 21

BrainStorm Cell Therapeutics Q2 2022 Earnings Preview

Aug 12

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Aug 05
Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Mar 22
Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Nov 26
Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?

Brainstorm Cell Therapeutics: MSC-NTF Cell Therapy Shows Mid-Stage Promise In PMS

May 30

Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Deliver On Growth Plans?

May 02
Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Deliver On Growth Plans?

BrainStorm Cell Therapeutics EPS beats by $0.07

Apr 26

Who Has Been Buying Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares?

Feb 21
Who Has Been Buying Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares?

BrainStorm Cell Therapeutics EPS misses by $0.18

Feb 04

Here's Why We're Watching Brainstorm Cell Therapeutics' (NASDAQ:BCLI) Cash Burn Situation

Jan 17
Here's Why We're Watching Brainstorm Cell Therapeutics' (NASDAQ:BCLI) Cash Burn Situation

BrainStorm completes dosing in Phase 2 MS Study

Dec 18

BrainStorm launches NurOwn Expanded Access Program

Dec 14

What Percentage Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares Do Insiders Own?

Dec 13
What Percentage Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares Do Insiders Own?

BrainStorm's NurOwn flunks in late-stage ALS study

Nov 17

Shareholder Returns

BCLIUS BiotechsUS Market
7D17.6%0.9%0.4%
1Y-77.4%10.3%28.8%

Return vs Industry: BCLI underperformed the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: BCLI underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is BCLI's price volatile compared to industry and market?
BCLI volatility
BCLI Average Weekly Movement19.0%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: BCLI's share price has been volatile over the past 3 months.

Volatility Over Time: BCLI's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200042Chaim Lebovitshttps://www.brainstorm-cell.com

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases.

Brainstorm Cell Therapeutics Inc. Fundamentals Summary

How do Brainstorm Cell Therapeutics's earnings and revenue compare to its market cap?
BCLI fundamental statistics
Market capUS$29.40m
Earnings (TTM)-US$16.63m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BCLI income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$16.63m
Earnings-US$16.63m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.34
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did BCLI perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.